Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV),
pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with
hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. Patients in this study must be
taking lamivudine (3TC).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)